Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond

Alzheimer's disease (AD) is the most common neurodegenerative disease in the elderly worldwide. However, the complexity of AD pathogenesis leads to discrepancies in the understanding of this disease, and may be the main reason for the failure of AD drug development. Fortunately, many ongoing preclinical and clinical studies will continually open up avenues to unravel disease mechanisms and guide strategies for AD diagnosis and drug development. For example, immunotherapeutic strategies targeting amyloid-β (Aβ) and tau proteins were once deemed almost certainly effective in clinical treatment due to the excellent preclinical results. However, the repeated failures of clinical trials on vaccines and humanized…

• NN
  National Natural Science Foundation of China

  Awards: 81973297, 82073836, 81872841, 82003719
• SA
  Science and Technology Commission of Shanghai Municipality
• SJ
  Shanghai Jiao Tong University
• SO
  School of Medicine, Shanghai Jiao Tong University